SCHEMBL4172460

SCHEMBL4172460

C(=C1c2ccccc2CCc2ccsc21)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.46
MAPT P10636 5/20 0.41
MIF P14174 3/20 0.41
NR3C1 P04150 1/20 0.40
PGR P06401 1/20 0.40
NR3C2 P08235 1/20 0.40
AR P10275 1/20 0.40
CYP19A1 P11511 4/20 0.40
CYP11B2 P19099 4/20 0.40
CYP11B1 P15538 3/20 0.40
KMT2A Q03164 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
PKM P14618 2/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
STAT3 P40763 1/20 0.39
STAT1 P42224 1/20 0.39
SLC6A2 P23975 4/20 0.39
CYP3A4 P08684 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4172455 1.00 MAOB (0.46) MAOBMAPTMIFNR3C1PGR
SCHEMBL8353049 0.85 NR3C1 (0.45) MAOBMAPTMIFNR3C1PGR
SCHEMBL14092367 0.85 NR3C1 (0.43) MAOBMAPTMIFNR3C1PGR
SCHEMBL13802908 0.85 NR3C1 (0.43) MAOBMAPTMIFNR3C1PGR
SCHEMBL13802885 0.85 MIF (0.54) MAOBMAPTMIFNR3C1PGR
SCHEMBL13801989 0.81 LMNA (0.47) MAOBMAPTMIFNR3C1PGR
SCHEMBL4172463 0.81 LMNA (0.47) MAOBMAPTMIFNR3C1PGR
SCHEMBL4172464 0.81 LMNA (0.47) MAOBMAPTMIFNR3C1PGR
SCHEMBL13802914 0.78 NR3C1 (0.58) NR3C1PGRNR3C2ARKMT2A
SCHEMBL5109816 0.77 CES1 (0.46) MAOBMAPTKMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2006-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS NR5A1, NR3C2, NR3C1 MAOB 2154/4885MAPT 3591/4885MIF 1642/4885
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators NR5A1, NR3C2, NR3C1 MAOB 2012/4885MAPT 3416/4885MIF 1592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.